Telehealth providers in Indiana
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
Telehealth prescribing is allowed in Indiana. What Indiana requires of telehealth prescribers and pharmacies, plus listings with their verification status.
Indiana at a glance
- Pharmacy regulator
- Indiana Board of Pharmacy (Indiana Professional Licensing Agency)
- 503A framework
- Follows the federal 503A framework
- Telehealth prescribing
- Regulatory: Telehealth allowed
- Asynchronous prescribing
- Regulatory: Async unclear
- Compounded GLP-1 access
- Regulatory: Compounded GLP-1 limited
Telehealth providers serving Indiana
Prescription peptides through an online assessment and a licensed provider review, shipped from a licensed U.S. compounding pharmacy.
Telehealth provider · 17 products · partner lists from $172 a month · Says it serves Indiana (not yet confirmed)
- Prescription only, no research-use-only sales
- Public cancellation and refund policy
We may earn a commission from these links.
Telehealth prescribing rules in Indiana
Indiana Code 25-1-9.5 (Telehealth Services and Prescriptions) holds a practitioner who uses telehealth to the in-person standard and requires a proper provider-patient relationship, which at a minimum means obtaining the patient's name, contact information, and location, verifying identity as far as reasonably possible, disclosing the practitioner's name and license, getting informed consent, obtaining the medical history needed for a diagnosis, discussing the diagnosis, the evidence for it, and the risks and benefits of treatment options with the patient, keeping a medical record, giving follow-up instructions, and providing a visit summary that lists any prescription (section 7). Section 8 lets a prescriber issue a prescription to a telehealth patient the prescriber has never examined in person if the standard of care is met and the drug is not an opioid (other than an approved opioid dependence drug) or an abortion inducing drug. It names a real-time, two-way audiovisual system only in the conditions for controlled substances, although section 8(a)(3)(A) says a prescription must meet the requirements of subsection (b), which is where that condition sits. Telehealth providers must hold an Indiana license (IC 25-1-9.5-3.5). Section 6 defines telehealth to include store and forward technology, but says that, unless the practitioner already has an established relationship with the patient, telehealth does not include electronic mail, an instant messaging conversation, facsimile, an Internet questionnaire, or an Internet consultation. This record leaves asynchronous prescribing unknown because the law is ambiguous: store and forward counts as telehealth and no real-time visit is named for non-controlled drugs, yet the online channels an asynchronous visit with a new patient would normally use are excluded and the practitioner must discuss the diagnosis with the patient. An Internet questionnaire with a new patient does not count as telehealth. [2]
Compounded GLP-1 access in Indiana
Compounded semaglutide and tirzepatide are limited to documented patient-specific needs after the FDA shortage allowances ended in 2025, and Indiana's 2026 law adds sourcing rules (FDA-registered bulk manufacturers with certificates of analysis) that exclude the unregistered active ingredient suppliers behind many cheap compounded GLP-1 products. Medical spas offering GLP-1 injections will need to register with the Medical Licensing Board from January 1, 2027. [6] [9]
Research use only sellers in Indiana
Only Indiana-licensed pharmacies, including licensed nonresident pharmacies, may dispense prescription drugs to Indiana patients, and Senate Enrolled Act 282 (2026) requires compounders to source bulk substances from FDA-registered establishments. Indiana Code 16-42-22.5, added by that act, expressly bars compounding with a research grade bulk substance outside an IRB-approved study. "Research use only" peptides sold for human injection are unapproved new drugs under federal law, are not dispensed by a pharmacist, and do not meet Indiana's new sourcing standard. [3] [6] [7] [10]
How to check a telehealth provider in Indiana
- Confirm the prescriber is licensed or registered to treat patients located in Indiana; the telehealth rules above explain what Indiana requires. [2]
- Ask which pharmacy will fill the prescription and check it in the Indiana Board of Pharmacy (Indiana Professional Licensing Agency) license lookup. [1] [3] [4] [6] [7] [8]
- Get the full price in writing first: consult fees, membership fees, and the medication itself.
- Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Indiana. [3] [6] [7] [10]
Common questions in Indiana
Can I start GLP-1 treatment in Indiana through telehealth?
Yes. Indiana Code 25-1-9.5 lets an Indiana-licensed prescriber issue a prescription to a telehealth patient the prescriber has not examined in person, provided they verify who and where you are, keep a medical record, and meet the standard of care. The chapter does not settle whether a visit with no live contact is enough for a new patient. It counts store and forward technology as telehealth, but an Internet questionnaire with a new patient does not count as telehealth, and the practitioner must discuss the diagnosis with you. [2] [5]
Sources
- [1]Indiana Board of Pharmacy, Indiana Professional Licensing Agency
- [2]Indiana Code 25-1-9.5, Telehealth services and prescriptions (Indiana General Assembly, 2026 Indiana Code)
- [3]Senate Enrolled Act 282 (2026), enrolled text, Public Law 136, adding Indiana Code 16-42-22.5
- [4]856 Indiana Administrative Code Article 1, Pharmacies and Pharmacists (including Rule 30, sterile pharmaceuticals)
- [5]Indiana Professional Licensing Agency: telehealth
- [6]Indiana General Assembly, Senate Bill 282 (2026), Compounding drugs; registration of medical spas
- [7]Indiana Code Title 25, Article 26, Chapter 17, Nonresident pharmacies
- [8]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
- [9]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
- [10]21 U.S.C. 331, Prohibited acts